Affimed Gmbh

Amphivena Therapeutics, Inc.

Affirmed Gmbh

Michael Weichel

Uwe Reusch

Ivica Fucek

Kristina Ellwanger

Stefan Knackmuss

Erich Rajkovic

Melvyn Little

Eugene Zhukovsky

Luke Evnin

Jeanmarie Guenot

Martin Treder

Judith A Fox

Lori Kunkel

Thorsten Ross

Vera Molkenthin

Claudia Wall

Michael Koslowski

Korden Walter

Stefan Woll

Maria Kreuzberg

Bernd Hubner

Michael Erdeljan

Fabrice Le Gall

Markus Eser

Fionnuala McAleese-Eser

Thomas Mueller

Fionnuala Mcaleese-Eser

Thorsten Gantke

Ugur Sahin

Ozlem Tureci

The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCM.

Tandem diabody for CD16A-directed NK-cell engagement

The application pertains to a trispecific antibody molecule which may comprise a diabody-unit integrated into a polypeptide chain having at least six variable domains linked one after another. In certain instances two single-chain Fv (scFv) fragments are distally connected to the diabody-unit providing two further antigen binding sites (FIGS.and).

Multivalent FV antibodies

Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33cancers, diseases and conditions such as acute myeloid leukemia (AML).

Bispecific CD33 and CD3 binding proteins

The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.

CD3 binding domains

Growing community of inventors

Bischofsheim, Germany

Michael Weichel